Activity and research directory projects

The directory lists antimicrobial resistance (AMR) activities and research and displays whether they are in progress or completed. Use the filters and search to help refine your query.

23 activities or research projects found
  • 2 August 2019
    The two main objectives of this project is: 1) to engineer micro- and nano-surfaces with enhanced anti-microbial properties and 2) to develop novel technologies to include such functional micro and nano-surfaces on "real-life" objects, overcoming the limitation of micro and nanotechnologies to small areas and flat surfaces.
    Monash University
  • 29 July 2019
    Expert veterinarians have published guidelines (for Australian pig veterinarians) on prescribing antimicrobials for use in pigs. The guidelines have been developed specifically for Australian conditions and reference the most contemporary knowledge available on AMR.
    Australian Veterinary Association
  • 9 July 2019
    Neisseria gonorrhoeae, the etiological agents of gonorrhoea, is now resistant to all available antibiotics. In the last three years, we have discovered how Neisseria bacteria escape the immune system to cause disease. We are now focused on harnessing this knowledge to develop new options that activate the immune system to control infections.
    Monash University
  • 1 July 2019
    This project aims to employ novel approaches to discover new-generation polymyxin antibiotics targeting the deadly Gram-negative ‘superbugs’. Novel lead molecules have been licensed to Qpex Biopharma (US) for IND-enabling evaluations with a Phase-I study aimed at 2020.
    Monash University and I (Jian Li, Professor, PhD) am the principal investigator. My project is currently funded by the American National Institutes of Health (NIH). More information at https://www.monash.edu/discovery-institute/news-and-events/news/2019-articles/us-biopharmaceutical-company-licenses-monash-university-superbug-drug-discovery
  • 29 June 2019
    Glycopeptide antibiotics – which include vancomycin – are last-resort antibiotics used in the clinic to treat serious Gram-positive bacterial infections. In this project, my team are utilising a novel chemo-enzymatic formation route that we have pioneered to generate and explore the properties of new vancomycin derivatives. This will allow us to explore the structure/ function relationships of these crucial antibiotics and to overcome growing bacterial resistance against these compounds.
    Monash University
  • 29 June 2019
    In this project, my team is developing a new approach to tackling antimicrobial resistance that exploits alternate mechanisms to overcome bacterial infections through augmentation of host immune responses and removal of bacterial evasion mechanisms. Our simultaneous “drug-immune” therapies will provide highly synergistic bacterial killing utilising existing antibiotic therapeutics, thus underlining the feasibility of future clinical application of such approaches.
    Monash University
  • 27 June 2019
    We are working with clinicians in the Center for Innovative Phage Applications and Therapeutics at the University of California in San Diego. Phage therapy is frontier medicine, and has FDA approval for use in hospitals in the USA. Isolating clinically-effective "cocktails" is a challenge that can only be met by collaboration between research scientists trained in phage biology (Monash) and clinicians with experience in clinical deployment (UCSD).
    Monash University.
    University of California in San Diego.
  • 27 June 2019
    We have engaged with partners in Wenzhou, China to analyze the recent rise in AMR in their hospitals. In 2019, we opened the Monash BDI-WMU Alliance in Clinical and Experimental Biomedicine on the campus of Wenzhou Medical University. Initial assessments of one species of bacteria reveals that 15 years ago, less than ten patients per annum were infected, all of which responded to off the shelf antibiotics. Last year, 990 patients had infections s, with ~1 in 3 being AMR.
    Biomedicine Discovery Institute, Monash University, Australia.
    Wenzhou Medical University, China.
  • 1 September 2018
    Antimicrobial Resistance: Science, Communication and Public Engagements (AMR-scapes) is funded by an Australian Research Council Discovery Project grant (DP170100937) to research public engagements with advice regarding the rational and reduced use of antibiotics. The project is led by Mark Davis, Andrea Whittaker, Mia Lindgren (Monash University), Monika Djerf-Pierre (University of Gothenburg and Monash University), and Paul Flowers (Glasgow Caledonian University).
    Monash University
  • 7 August 2018
    This PhD research project is aimed at investigating alternative regulatory and funding models for antimicrobial drugs. The current economic model (where sales volumes and price determine the return on investment for a drug) does not foster appropriate antimicrobial use. Financial risks associated with AMR has resulted in a decline in the marketing of new drugs & insecurity of supply of current antimicrobials. This project is focused on the Australian market within a global context.
    University of Adelaide

Pages